Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Maat Pharma SA (MAAT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.00 +0.80    +15.38%
10:46:20 - Real-time Data. Currency in EUR
Type:  Equity
Market:  France
ISIN:  FR0012634822 
  • Volume: 47,991
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 5.58 - 6.08
Maat Pharma 6.00 +0.80 +15.38%

Maat Pharma SA Company Profile

 
Get an in-depth profile of Maat Pharma SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

54

Equity Type

ORD

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.

Contact Information

Address 70 Avenue Tony Garnier
Lyon, 69007
France
Phone 33 4 28 29 14 00
Fax -

Top Executives

Name Age Since Title
Pierre Belichard - - Co-Founder and Chairman of the Board
Herve Affagard 51 2014 CEO, Co-Founder & Director
Joel Dore - - Co-Founder & Member of Scientific Advisory Board
Robert Zeiser - 2020 Member of Scientific Advisory Board
Ernst Holler - 2020 Chair of Scientific Advisory Board
Robert Jenq - 2020 Member of Scientific Advisory Board
Dorothee Burkel 61 2021 Independent Non Executive Director
Florent Malard - 2020 Member of Scientific Advisory Board
Jean Volatier 60 2021 Independent Non Executive Director
Jean-Marie Lefevre 65 2016 Chairman of the Board
Hassane Zarour - 2022 Member of Scientific Advisory Board
Jonathan Peled - - Member of Advisory Board
Nadia Kamal 54 2023 Independent Director
Claude Bertrand 63 2020 Independent Non-Executive Director
Isabelle de Cremoux 55 2014 Representative Director
Muriel Prudent 39 - Representative Director
Mohamad Mohty - - Member of Advisory Board (Medical Hematology – Oncology Advisor)
Franck Carbonnel - 2022 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MAAT Comments

Write your thoughts about Maat Pharma SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email